The significance of targeting ABCG2 (also known as breast cancer resistance protein/BCRP) in breast cancer (Zattoni et al., 2022) and prostate cancer (Sabnis et al., 2017) also been reported. The gene discussed is ABCG2; the disease is prostate carcinoma.